Hepatitis C and Liver Transplantation: Enhancing Outcomes and Should Patients Be Retransplanted

Unos Forman, 2002, The association between hepatitis C infection and survival after orthotopic liver transplantation, Gastroenterology, 122, 889, 10.1053/gast.2002.32418 Berenguer, 2000, Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation, Hepatology, 32, 852, 10.1053/jhep.2000.17924 Berenguer, 2000, HCV-related fibrosis progression following liver transplantation: increase in recent years, J Hepatol, 32, 673, 10.1016/S0168-8278(00)80231-7 Merion, 2005, The survival benefit of liver transplantation, Am J Transplant, 5, 307, 10.1111/j.1600-6143.2004.00703.x Renz, 2005, Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation, Ann Surg, 242, 556, 10.1097/01.sla.0000183973.49899.b1 Tector, 2006, Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival, Ann Surg, 244, 439, 10.1097/01.sla.0000234896.18207.fa Cameron, 2006, Optimal utilization of donor grafts with extended criteria: a single-center experience in over 1000 liver transplants, Ann Surg, 243, 748, 10.1097/01.sla.0000219669.84192.b3 Cescon, 2003, Long-term survival of recipients of liver grafts from donors older than 80 years: is it achievable?, Liver Transpl, 9, 1174, 10.1053/jlts.2003.50234 Zhao, 2004, Use of elderly donors (>60 years) for liver transplantation, Asian J Surg, 27, 114, 10.1016/S1015-9584(09)60323-7 Lake, 2005, Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis, Am J Transplant, 5, 549, 10.1111/j.1600-6143.2005.00741.x Berenguer, 2002, Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients, Hepatology, 36, 202, 10.1053/jhep.2002.33993 Burak, 2002, Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C, Liver Transpl, 8, 362, 10.1053/jlts.2002.32282 Mutimer, 2006, Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus, Transplantation, 81, 7, 10.1097/01.tp.0000188619.30677.84 Castells, 1999, Transmission of hepatitis B virus by transplantation of livers from donors positive for antibody to hepatitis B core antigen, Transplant Proc, 31, 2464, 10.1016/S0041-1345(99)00419-4 Uemoto, 1998, Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors, Transplant Proc, 30, 134, 10.1016/S0041-1345(97)01211-6 Dickson, 1997, Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database, Gastroenterology, 113, 1668, 10.1053/gast.1997.v113.pm9352871 Nery, 2001, Are liver grafts from hepatitis B surface antigen negative/anti-hepatitis B core antibody positive donors suitable for transplantation?, Transplant Proc, 33, 1521, 10.1016/S0041-1345(00)02580-X Joya-Vazquez, 2002, Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis, Transplantation, 73, 1598, 10.1097/00007890-200205270-00013 Loss, 2001, Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results, Clin Transplant, 15, 55, 10.1034/j.1399-0012.2001.00010.x Boyacioglu, 2001, Is there risk of transmitting hepatitis B virus in accepting hepatitis B core antibody-positive donors for living related liver transplantation?, Transplant Proc, 33, 2802, 10.1016/S0041-1345(01)02196-0 Holt, 2002, Use of hepatitis B core antibody-positive donors in orthotopic liver transplantation, Arch Surg, 137, 572, 10.1001/archsurg.137.5.572 Suehiro, 2005, Prevention of hepatitis B virus infection from hepatitis B core antibody-positive donor graft using hepatitis B immune globulin and lamivudine in living donor liver transplantation, Liver Int, 25, 1169, 10.1111/j.1478-3231.2005.01165.x Dodson, 1999, Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors, Transplantation, 68, 1058, 10.1097/00007890-199910150-00028 Celebi Kobak, 2007, Living donor liver transplantation from hepatitis B core antibody positive donors, Transplant Proc, 39, 1488, 10.1016/j.transproceed.2006.11.015 Roque-Afonso, 2002, Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBc positive donors, Gut, 50, 95, 10.1136/gut.50.1.95 Nery, 2003, Use of liver grafts from donors positive for antihepatitis B-core antibody (anti-HBc) in the era of prophylaxis with hepatitis-B immunoglobulin and lamivudine, Transplantation, 75, 1179, 10.1097/01.TP.0000065283.98275.FE Arenas, 2003, The use of hepatitis C-infected grafts in liver transplantation, Liver Transpl, 9, S48, 10.1053/jlts.2003.50252 Saab, 2003, Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation, Liver Transpl, 9, 1053, 10.1053/jlts.2003.50208 Saab, 2003, Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis, Am J Transplant, 3, 1167, 10.1034/j.1600-6143.2003.00189.x Salizzoni, 2001, Outcome of patients transplanted with liver from hepatitis C positive donors, Transplant Proc, 33, 1507, 10.1016/S0041-1345(00)02821-9 Vargas, 1999, Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts, Gastroenterology, 117, 149, 10.1016/S0016-5085(99)70561-5 Velidedeoglu, 2001, Effect of donor hepatitis C on liver graft survival, Transplant Proc, 33, 3795, 10.1016/S0041-1345(01)02606-9 Testa, 1998, Long-term outcome of patients transplanted with livers from hepatitis C-positive donors, Transplantation, 65, 925, 10.1097/00007890-199804150-00011 Marroquin, 2001, Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers, Liver Transpl, 7, 762, 10.1053/jlts.2001.27088 Abt, 2004, Survival following liver transplantation from non-heart-beating donors, Ann Surg, 239, 87, 10.1097/01.sla.0000103063.82181.2c Manzarbeitia, 2004, Long-term outcome of controlled, non-heart-beating donor liver transplantation, Transplantation, 78, 211, 10.1097/01.TP.0000128327.95311.E3 Quintela, 2005, Long-term results for liver transplantation from non-heart-beating donors maintained with chest and abdominal compression-decompression, Transplant Proc, 37, 3857, 10.1016/j.transproceed.2005.10.039 Brown, 2003, A survey of liver transplantation from living adult donors in the United States, N Engl J Med, 348, 818, 10.1056/NEJMsa021345 Liu, 2003, Impact of right-lobe live donor liver transplantation on patients waiting for liver transplantation, Liver Transpl, 9, 863, 10.1053/jlts.2003.50163 Russo, 2004, Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation, Am J Transplant, 4, 427, 10.1111/j.1600-6143.2004.00336.x Everson, 2003, Treatment of patients with hepatitis C virus on the waiting list, Liver Transpl, 9, S90, 10.1053/jlts.2003.50247 Everson, 2005, Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy, Hepatology, 42, 255, 10.1002/hep.20793 Gaglio, 2003, Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors, Liver Transpl, 9, 1028, 10.1053/jlts.2003.50211 Garcia-Retortillo, 2004, Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation, Hepatology, 40, 699, 10.1002/hep.20357 Russo, 2004, Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States, Liver Transpl, 10, 340, 10.1002/lt.20090 Shiffman, 2004, Histologic recurrence of chronic hepatitis C virus in patients after living donor and deceased donor liver transplantation, Liver Transpl, 10, 1248, 10.1002/lt.20232 Schiano, 2005, Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors, Hepatology, 42, 1420, 10.1002/hep.20947 Guo, 2006, Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients, Liver Transpl, 12, 560, 10.1002/lt.20660 Takada, 2006, Clinical outcomes of living donor liver transplantation for hepatitis C virus (HCV)-positive patients, Transplantation, 81, 350, 10.1097/01.tp.0000197554.16093.d1 Terrault, 2007, Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation, Liver Transpl, 13, 122, 10.1002/lt.20995 Olthoff Km, 2005, Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium, Ann Surg, 242, 314, 10.1097/01.sla.0000179646.37145.ef Miller, 2004, Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor, Liver Transpl, 10, 1315, 10.1002/lt.20227 Russo, 2004, Adult living donor liver transplantation, Am J Transplant, 4, 458, 10.1111/j.1600-6143.2004.00387.x Rudow, 2003, Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors, Liver Transpl, 9, 254, 10.1053/jlts.2003.50037 Verna, 2005, Predictors of candidate maturation among potential living donors, Am J Transplant, 5, 2549, 10.1111/j.1600-6143.2005.01066.x Berenguer, 2002, Natural history of recurrent hepatitis C, Liver Transpl, 8, S14, 10.1053/jlts.2002.35781 Charlton, 1998, Predictors of patient and graft survival following liver transplantation for hepatitis C, Hepatology, 28, 823, 10.1002/hep.510280333 Charlton, 2004, Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database, Liver Transpl, 10, 1120, 10.1002/lt.20211 Rosen, 1997, Cytomegalovirus viremia: risk factor for allograft cirrhosis after liver transplantation for hepatitis C, Transplantation, 64, 721, 10.1097/00007890-199709150-00010 Wiesner, 2003, Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C, Liver Transpl, 9, S1, 10.1053/jlts.2003.50268 Everson, 2004, Treatment of chronic hepatitis C in patients with decompensated cirrhosis, Rev Gastroenterol Disord, 4, S31 Forns, 2003, Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation, J Hepatol, 39, 389, 10.1016/S0168-8278(03)00310-6 Shiffman, 2004, Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment, Gastroenterology, 126, 1015, 10.1053/j.gastro.2004.01.014 Crippin, 2002, A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation, Liver Transpl, 8, 350, 10.1053/jlts.2002.31748 Everson, 2005, Should we treat patients with chronic hepatitis C on the waiting list?, J Hepatol, 42, 456, 10.1016/j.jhep.2005.01.012 Davis, 2005, A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients, Liver Transpl, 11, 941, 10.1002/lt.20405 Schiano, 2006, Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study, Liver Transpl, 12, 1381, 10.1002/lt.20876 Davis, 2006, Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills?, Liver Transpl, 12, 1317, 10.1002/lt.20889 Shergill, 2005, Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation, Am J Transplant, 5, 118, 10.1111/j.1600-6143.2004.00648.x Ahmad, 2001, Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin, Liver Transpl, 7, 863, 10.1053/jlts.2001.27869 Lavezzo, 2002, Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alfa 2b with ribavirin, J Hepatol, 37, 247, 10.1016/S0168-8278(02)00109-5 Samuel, 2003, Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study, Gastroenterology, 124, 642, 10.1053/gast.2003.50095 Sheiner, 1998, The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation, Hepatology, 28, 831, 10.1002/hep.510280334 Chalasani, 2005, Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials, Hepatology, 41, 289, 10.1002/hep.20560 Gane, 1998, A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation, Hepatology, 27, 1403, 10.1002/hep.510270530 Feray, 1995, An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection, Hepatology, 22, 1084, 10.1002/hep.1840220411 Rodriguez-Luna, 2004, Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series, Transplantation, 77, 190, 10.1097/01.TP.0000100481.14514.BB Ross, 2004, Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C, Clin Transplant, 18, 166, 10.1046/j.1399-0012.2003.00145.x Saab, 2004, Outcomes of acute rejection after interferon therapy in liver transplant recipients, Liver Transpl, 10, 859, 10.1002/lt.20157 Toniutto, 2005, Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: comparison of tolerability and efficacy, J Gastroenterol Hepatol, 20, 577, 10.1111/j.1440-1746.2005.03795.x Stravitz, 2004, Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation, Liver Transpl, 10, 850, 10.1002/lt.20189 Mukherjee, 2003, Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation, Transplant Proc, 35, 3042, 10.1016/j.transproceed.2003.10.083 Dumortier, 2004, Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination, J Hepatol, 40, 669, 10.1016/j.jhep.2003.12.015 Beckebaum, 2004, Combination therapy with peginterferon alpha-2b and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study, Transplant Proc, 36, 1489, 10.1016/j.transproceed.2004.05.017 Neff, 2004, Treatment of established recurrent hepatitis C in liver-transplant recipients with pegylated interferon-alfa-2b and ribavirin therapy, Transplantation, 78, 1303, 10.1097/01.TP.0000129811.93072.1C Castells, 2005, Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation, J Hepatol, 43, 53, 10.1016/j.jhep.2005.02.015 Babatin, 2005, Pegylated-interferon alpha 2b and ribavirin for recurrent hepatitis C after liver transplantation: from a Canadian experience to recommendations for therapy, Can J Gastroenterol, 19, 359, 10.1155/2005/745197 Berenguer, 2006, Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C, Liver Transpl, 12, 1067, 10.1002/lt.20737 Moreno Planas, 2005, Peginterferon and ribavirin in patients with HCV cirrhosis after liver transplantation, Transplant Proc, 37, 2207, 10.1016/j.transproceed.2005.03.124 Sharma, 2007, Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence, Liver Transpl, 13, 1100, 10.1002/lt.21121 Angelico, 2007, A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C, J Hepatol, 46, 1009, 10.1016/j.jhep.2006.12.017 Wang, 2006, Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis, Am J Transplant, 6, 1586, 10.1111/j.1600-6143.2006.01362.x Bizollon T, 2005, Benefit of sustained virological response to combination therapy on graft survival of liver transplanted patients with recurrent chronic hepatitis C, Am J Transplant, 5, 1909, 10.1111/j.1600-6143.2005.00976.x Carrion, 2007, Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study, Gastroenterology, 132, 1746, 10.1053/j.gastro.2007.03.041 Saab, 2002, Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients?, Liver Transpl, 8, 449, 10.1053/jlts.2002.32717 Charlton, 1999, Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database, Liver Transpl Surg, 5, S107 Neumann, 2004, Fibrosis progression after liver transplantation in patients with recurrent hepatitis C, J Hepatol, 41, 830, 10.1016/j.jhep.2004.06.029 Sheiner, 1995, Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation, Hepatology, 21, 30, 10.1002/hep.1840210107 Rosen, 1997, Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation, Am J Gastroenterol, 92, 1453 Berenguer, 1998, Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection, J Hepatol, 28, 756, 10.1016/S0168-8278(98)80224-9 Nelson, 2001, Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation, Liver Transpl, 7, 1064, 10.1053/jlts.2001.29414 Gane, 1996, A longitudinal analysis of hepatitis C virus replication following liver transplantation, Gastroenterology, 110, 167, 10.1053/gast.1996.v110.pm8536853 Watashi, 2003, Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes, Hepatology, 38, 1282, 10.1053/jhep.2003.50449 Martin, 2004, Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial, Liver Transpl, 10, 1258, 10.1002/lt.20222 Ghobrial, 2001, A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients, Ann Surg, 234, 384, 10.1097/00000658-200109000-00012 Terrault, 2000, Hepatitis C virus and liver transplantation, Semin Gastrointest Dis, 11, 96 Zervos, 1998, Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation, Transplantation, 65, 1044, 10.1097/00007890-199804270-00006 Levy, 2004, Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation, Transplantation, 77, 1632, 10.1097/01.TP.0000129095.51031.42 Fisher, 2004, Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation, Clin Transplant, 18, 463, 10.1111/j.1399-0012.2004.00192.x Berenguer, 2006, Effect of calcineurin inhibitors on survival and histologic disease severity in HCV-infected liver transplant recipients, Liver Transpl, 12, 762, 10.1002/lt.20655 Berenguer, 2007, Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis, Liver Transpl, 13, 21, 10.1002/lt.21035 Wiesner, 2001, A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients, Liver Transpl, 7, 442, 10.1053/jlts.2001.23356 Jain, 2002, A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C, Liver Transpl, 8, 40, 10.1053/jlts.2002.29763 Bahra, 2005, MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: impact on histological course, Am J Transplant, 5, 406, 10.1111/j.1600-6143.2004.00706.x Zekry, 2004, A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection, Liver Transpl, 10, 52, 10.1002/lt.20000 Eason, 2003, Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy, Transplantation, 75, 1396, 10.1097/01.TP.0000062834.30922.FE Marcos, 2004, Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus, Transplantation, 78, 966, 10.1097/01.TP.0000142674.78268.01 Filipponi, 2004, Double-blind comparison of hepatitis C histological recurrence rate in HCV+ liver transplant recipients given basiliximab + steroids or basiliximab + placebo, in addition to cyclosporine and azathioprine, Transplantation, 78, 1488, 10.1097/01.TP.0000140881.07208.4E Belli, 2003, Tapering off steroids three months after liver transplantation is not detrimental for hepatitis C virus disease recurrence, Liver Transpl, 9, 201, 10.1053/jlts.2002.50033 Llado, 2006, Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study, J Hepatol, 44, 710, 10.1016/j.jhep.2005.12.010 Navasa, 1996, Diabetes mellitus after liver transplantation: prevalence and predictive factors, J Hepatol, 25, 64, 10.1016/S0168-8278(96)80329-1 Boillot, 2005, Corticosteroid-free immunosuppression with tacrolimus following induction with Daclizumab: a large randomized clinical study, Liver Transpl, 11, 61, 10.1002/lt.20307 Baid, 2001, Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality, Transplantation, 72, 1066, 10.1097/00007890-200109270-00015 Tisone, 2006, Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence, J Hepatol, 44, 702, 10.1016/j.jhep.2005.11.047 Berenguer, 2006, Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression, J Hepatol, 44, 717, 10.1016/j.jhep.2006.01.005 Brillanti, 2002, Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation, Liver Transpl, 8, 884, 10.1053/jlts.2002.34640 Burton, 2005, Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States, Clin Gastroenterol Hepatol, 3, 700, 10.1016/S1542-3565(05)00158-8 Biggins, 2003, Should HCV-related cirrhosis be a contraindication for retransplantation?, Liver Transpl, 9, 236, 10.1053/jlts.2003.50048 Azoulay, 2002, Decision for retransplantation of the liver: an experience- and cost-based analysis, Ann Surg, 236, 713, 10.1097/00000658-200212000-00003 Watt, 2003, Poor survival after liver retransplantation: is hepatitis C to blame?, Liver Transpl, 9, 1019, 10.1053/jlts.2003.50206 Pelletier, 2005, Hepatitis C is a risk factor for death after liver retransplantation, Liver Transpl, 11, 434, 10.1002/lt.20342 Rosen, 1999, A model to predict survival following liver retransplantation, Hepatology, 29, 365, 10.1002/hep.510290221 Markmann, 1997, Long-term survival after retransplantation of the liver, Ann Surg, 226, 408, 10.1097/00000658-199710000-00002 McCashland, 2003, Retransplantation for recurrent hepatitis C: positive aspects, Liver Transpl, 9, S67, 10.1053/jlts.2003.50249 Ghobrial, 2002, Pretransplant model to predict posttransplant survival in liver transplant patients, Ann Surg, 236, 315, 10.1097/00000658-200209000-00008 McCashland, 2007, Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study, Liver Transpl, 13, 1246, 10.1002/lt.21322 Rosen, 1998, Hepatitis C infection in patients undergoing liver retransplantation, Transplantation, 66, 1612, 10.1097/00007890-199812270-00007 Neff, 2004, Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection, Liver Transpl, 10, 1497, 10.1002/lt.20301 Rosen, 2003, Validation and refinement of survival models for liver retransplantation, Hepatology, 38, 460, 10.1053/jhep.2003.50328 Doyle, 1996, Hepatic retransplantation—an analysis of risk factors associated with outcome, Transplantation, 61, 1499, 10.1097/00007890-199605270-00016 Burton, 2004, Retransplantation for recurrent hepatitis C in the MELD era: maximizing utility, Liver Transpl, 10, S59, 10.1002/lt.20259 Watt, 2005, Mortality while awaiting liver retransplantation: predictability of MELD scores, Transplant Proc, 37, 2172, 10.1016/j.transproceed.2005.03.004 Yao, 2004, Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores, Hepatology, 39, 230, 10.1002/hep.20005 Busuttil, 2005, Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience, Ann Surg, 241, 905, 10.1097/01.sla.0000164077.77912.98 Markmann, 1999, A simple model to estimate survival after retransplantation of the liver, Transplantation, 67, 422, 10.1097/00007890-199902150-00015 Zimmerman, 2005, When shouldn't we retransplant?, Liver Transpl, 11, S14, 10.1002/lt.20599 Feng, 2006, Characteristics associated with liver graft failure: the concept of a donor risk index, Am J Transplant, 6, 783, 10.1111/j.1600-6143.2006.01242.x Northup, 2007, Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index, Am J Transplant, 7, 1984, 10.1111/j.1600-6143.2007.01887.x